GlassScriptPhysician profile
Elizabeth Wang
NPI 1043695174
$3,683.35
in general payments reported to CMS, 2019-2025
19 companies · $2,732 in 2025
The $2,732 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $419 · 2021: $158 · 2022: $185 · 2023: $51.69 · 2024: $138 · 2025: $2,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,906 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,906.32 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $983.67 | 2020-2025 | |
| Galderma Laboratories, L.P. | $462.32 | 2025 | Nemluvio |
| Incyte Corporation | $396.44 | 2024-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $380.27 | 2020-2025 | Dupixent |
| Lilly USA, LLC | $252.34 | 2025 | Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $228.45 | 2025 | Zoryve |
| Genzyme Corporation | $204.93 | 2025 | |
| Allergan, INC. | $184.84 | 2022 | |
| Ucb, INC. | $148.37 | 2024-2025 | Bimzelx |
| Revance Therapeutics, INC. | $83.37 | 2025 | Daxi |
| Pfizer INC. | $78.05 | 2023-2025 | |
| Leo Pharma INC. | $65.05 | 2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $51.05 | 2025 | |
| Merz North America, INC. | $33.05 | 2025 | |
| Organon LLC | $30.77 | 2025 | Vtama |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgenex LLC | $30.35 | 2025 | Surgraft, Ardeograft, Renograft |
| Sun Pharmaceutical Industries INC. | $29.92 | 2025 | |
| Dermavant Sciences, INC. | $26.51 | 2024 | Vtama |
| Teva Pharmaceuticals USA, INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.